Praxis Pushes Ulixacaltamide Into Phase III For Essential Tremor, But Uncertainty Remains

 
• By Alaric DeArment
  
Praxis announced results from its Phase II study in essential tremor • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D